BACKGROUND: Controversy exists regarding type 2 diabetes (T2D) remission rates after bariatric surgery (BS) due to heterogeneity in its definition and patients' baseline features. We evaluate T2D remission using recent criteria, according to preoperative characteristics and insulin therapy (IT). METHODS: We performed a retrospective study from a cohort of 657 BS from a single center (2006-2011), of which 141 (57.4 % women) had T2D. We evaluated anthropometric and glucose metabolism parameters before surgery and at 1-year follow-up. T2D remission was defined according to 2009 consensus criteria: HbA1c <6%, fasting glucose (FG) <100 mg/dL, and absence of pharmacologic treatment. We analyzed diabetes remission according to previous treatment. RESULTS: Preoperative characteristic were (mean ± SD): age 53.9 ± 9.8 years, BMI 43.7 ± 5.6 kg/m2, T2D duration 7.4 ± 7.6 years, FG 160.0 ± 54.6 mg/dL, HbA1c 7.6 ± 1.6%. Fifty-six (39.7%) individuals had IT. At 1-year follow-up, 74 patients (52.5%) had diabetes remission. Percentage weight loss (%WL) and percentage excess weight loss (%EWL) were associated to remission (35.5 ± 8.1 vs. 30.2 ± 9.5 %, p = 0.001; 73.6 ± 18.4 vs. 66.3 ± 22.8%, p = 0.037, respectively). Duration of diabetes, age, and female sex were associated to nonremission: 10.3 ± 9.4 vs. 4.7 ± 3.8 years, p < 0.001; 55.1 ± 9.3 vs. 51.2 ± 9.9 years, p = 0.017; 58.9 vs. 33.3%, p = 0.004, respectively. Prior treatment revealed differences in remission rates: 67.1 % in case of oral therapy (OT) vs. 30.4% in IT, p < 0.001. OR for T2D remission in patients with previous IT, compared to those with only OT, were 0.157-0.327 (p < 0.05), adjusting by different models. CONCLUSIONS: Consensus criteria reveal lower T2D remission rates after BS than previously reported. Prior insulin use is a main setback for remission.
BACKGROUND: Controversy exists regarding type 2 diabetes (T2D) remission rates after bariatric surgery (BS) due to heterogeneity in its definition and patients' baseline features. We evaluate T2D remission using recent criteria, according to preoperative characteristics and insulin therapy (IT). METHODS: We performed a retrospective study from a cohort of 657 BS from a single center (2006-2011), of which 141 (57.4 % women) had T2D. We evaluated anthropometric and glucose metabolism parameters before surgery and at 1-year follow-up. T2D remission was defined according to 2009 consensus criteria: HbA1c <6%, fasting glucose (FG) <100 mg/dL, and absence of pharmacologic treatment. We analyzed diabetes remission according to previous treatment. RESULTS: Preoperative characteristic were (mean ± SD): age 53.9 ± 9.8 years, BMI 43.7 ± 5.6 kg/m2, T2D duration 7.4 ± 7.6 years, FG 160.0 ± 54.6 mg/dL, HbA1c 7.6 ± 1.6%. Fifty-six (39.7%) individuals had IT. At 1-year follow-up, 74 patients (52.5%) had diabetes remission. Percentage weight loss (%WL) and percentage excess weight loss (%EWL) were associated to remission (35.5 ± 8.1 vs. 30.2 ± 9.5 %, p = 0.001; 73.6 ± 18.4 vs. 66.3 ± 22.8%, p = 0.037, respectively). Duration of diabetes, age, and female sex were associated to nonremission: 10.3 ± 9.4 vs. 4.7 ± 3.8 years, p < 0.001; 55.1 ± 9.3 vs. 51.2 ± 9.9 years, p = 0.017; 58.9 vs. 33.3%, p = 0.004, respectively. Prior treatment revealed differences in remission rates: 67.1 % in case of oral therapy (OT) vs. 30.4% in IT, p < 0.001. OR for T2D remission in patients with previous IT, compared to those with only OT, were 0.157-0.327 (p < 0.05), adjusting by different models. CONCLUSIONS: Consensus criteria reveal lower T2D remission rates after BS than previously reported. Prior insulin use is a main setback for remission.
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Ricardo V Cohen; Jose C Pinheiro; Carlos A Schiavon; João E Salles; Bernardo L Wajchenberg; David E Cummings Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112
Authors: Ana M Ramos-Levi; Lucio Cabrerizo; Pilar Matía; Andrés Sánchez-Pernaute; Antonio J Torres; Miguel A Rubio Journal: BMC Surg Date: 2013-03-28 Impact factor: 2.102
Authors: Ana M Ramos-Leví; Andrés Sánchez-Pernaute; Clara Marcuello; Mercedes Galindo; Alfonso L Calle-Pascual; Antonio J Torres; Miguel A Rubio Journal: Obes Surg Date: 2017-12 Impact factor: 4.129
Authors: Camilo Boza; Patricio Valderas; David A Daroch; Felipe I León; José P Salinas; Diego A Barros; Ricardo A Funke; Fernando J Crovari Journal: Obes Surg Date: 2014-08 Impact factor: 4.129
Authors: Ana M Ramos-Levi; Andres Sanchez-Pernaute; Lucio Cabrerizo; Pilar Matia; Ana Barabash; Carmen Hernandez; Alfonso L Calle-Pascual; Antonio J Torres; Miguel A Rubio Journal: Obes Surg Date: 2013-12 Impact factor: 4.129
Authors: Macarena Torrego-Ellacuría; Ana Barabash; Angélica Larrad-Sainz; Gemma Maria Hernández-Nuñez; Pilar Matía-Martín; Natalia Pérez-Ferre; Clara Marcuello; Andrés Sánchez-Pernaute; Antonio José Torres; Alfonso Luis Calle-Pascual; Miguel Angel Rubio Journal: Obes Surg Date: 2021-06-19 Impact factor: 4.129